Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



**December 2, 2025** 

For immediate release

Company name: Kojima Co., Ltd. Representative: Yuji Nakazawa

Representative Director and President

Securities code: (Tokyo Stock Exchange, Prime Market: 7513)

Inquiries: Tadashi Arakawa

Representative Senior Managing Director,

General Manager of Corporate Planning Division

TEL: +81-(0)3-6907-3114

## Notice Concerning Determination of Issuance Details of Stock-Compensation-Type Share Options to Executive Officers and Employees

Kojima Co., Ltd. (the "Company") hereby announces, with respect to the stock-compensation-type share options (share acquisition rights) to be allotted to executive officers and employees of the Company, as resolved at the Board of Directors' meeting held on November 17, 2025, that the previously undetermined items were finalized today as outlined below.

- Total number of share acquisition rights
  356 rights
- 2. Recipients of allotment of share acquisition rights, number of recipients, and number of share acquisition rights to be allotted Executive officers and employees of the Company (at the managerial level or above): 54 persons, 356 rights
- 3. Amount to be paid in for share acquisition rights

114,900 yen per share acquisition right (1,149 yen per share)

The above amount represents the fair value calculated according to the Black-Scholes model on the date of allotment of the share acquisition rights. In lieu of making the payment of the amount to be paid in, the allottees of the share acquisition rights shall offset the amount to be paid in with their compensation claims against the Company.

4. Class and number of shares underlying the share acquisition rights Common shares of the company: 35,600 shares

## (Reference)

- (1) Introduction of a performance-based incentive system: November 14, 2018
- (2) Date of the Board of Directors' resolution determining the issuance terms: November 17, 2025
- (3) Date of allotment: December 2, 2025